Neuropace Inc Stock Price, News & Analysis

NeuroPace (NPCE) has provided an update regarding its exposure to implemented tariffs, stating that it expects minimal impact on its operations and financial results. The company attributes this exposure to manufacturing and selling the majority of its devices within the United States, with minimal international supply chain activities for its RNS System.

The company also expects no material impact on gross margin for DIXI Medical SEEG products and is reiterating its gross margin guidance for 2025. NeuroPace has previously announced the termination of its SEEG distribution agreement with DIXI Medical, effective October 1, 2025, followed by a six-month wind-down period through Q1 2026.

The company will report its Q1 2025 financial results on May 13, 2025, after market close, followed by a conference call at 1:30 p.m. Pacific Time.

NeuroPace (NPCE) has announced significant three-year effectiveness data from their Post-Approval Study (PAS) of the RNS® System at the 2025 AAN Annual Meeting. The study, involving 324 patients across 32 centers, represents the largest FDA-reviewed prospective neuromodulation trial for drug-resistant focal epilepsy.

Key findings include:

• 82% median seizure reduction at 3 years
• 62% median seizure reduction at 6 months
• 42% of patients remained seizure-free for 6+ months
• 1 in 3 patients did not require intracranial EEG monitoring

The RNS System, the only FDA-approved epilepsy device providing brain-responsive neurostimulation, addresses drug-resistant epilepsy (DRE), which affects approximately 1.2 million people in the U.S. The three-year safety and effectiveness data were submitted to the FDA in November 2024, with the study continuing to five years.

NeuroPace (NPCE) announced it will present three-year data from its Post-Approval Study (PAS) of the RNS® System at the 2025 American Academy of Neurology Annual Meeting in San Diego. The presentation will focus on results in adults treated with brain-responsive stimulation for drug-resistant focal epilepsy (DRE).

The RNS System, the first and only neuromodulation platform delivering personalized, real-time seizure treatment, will be showcased at booth #1642. Key presentations include an oral session on April 7 by Dr. Dawn Eliashiv, an Exhibitor Hall presentation on April 8 by Dr. Martha Morrell and Dr. Barbara Jobst, and encore webinars on April 8 and 11 for those unable to attend in person.

NeuroPace (NPCE) announced a strategic refocusing of its product portfolio, terminating its SEEG products distribution relationship with DIXI Medical in Q4 2025. The company will maintain its focus on its core RNS System product line.

The company reaffirmed its 2025 revenue guidance and long-range plan expectations, including:

• 20%+ revenue CAGR
• Cash flow breakeven target by end of 2027
• Gross margin improvement (RNS System >78% vs SEEG ~50%)

Key growth initiatives for 2026 include:

• Project CARE site of service expansion
• Indication expansion into drug-resistant idiopathic generalized epilepsy
• Expansion into pediatric focal epilepsy
• Launch of AI-enabled software products

NeuroPace (Nasdaq: NPCE), a medical device company specializing in epilepsy treatment solutions, has announced its upcoming participation in the 24th Annual Needham Virtual Healthcare Conference. The company's management team is scheduled to present on Tuesday, April 8, 2025, at 3:00 PM ET (12:00 PM PT).

The presentation will be available through a live webcast, and investors will have the opportunity to participate in one-on-one meetings with management during the conference. For those unable to attend live, a replay of the webcast will remain accessible for 90 days following the presentation in the Events section of NeuroPace's Investor website.

NeuroPace (NPCE) reported strong Q4 2024 financial results with record quarterly revenue of $21.5 million, up 19% year-over-year. Full-year 2024 revenue increased 22% to $79.9 million.

The company completed a public offering of $74.8 million, using $49.5 million to repurchase KCK holdings and $20.2 million to strengthen its balance sheet. Gross margin reached 73.9% in 2024, while operating expenses were $80.8 million.

Key developments include:

• NAUTILUS pivotal study completion expected March 2025
• Project CARE showing increased implants and referrals
• New NEST program using real-world data from 27 pediatric centers
• Development of AI-enabled software tools and remote programming

For 2025, NeuroPace projects revenue between $92-96 million, representing 15-20% growth, with gross margin expected between 73-75%.

NeuroPace (Nasdaq: NPCE), a medical device company specializing in epilepsy treatment solutions, has announced its participation in the upcoming Leerink Partners 2025 Global Healthcare Conference. The company's management team is scheduled to present on Monday, March 10, 2025, at 4:20pm ET (1:20pm PT) in Miami, FL.

The presentation will be available through a live webcast, with a replay accessible for two weeks afterward through the Events section of NeuroPace's Investor website. Additionally, the management team will be conducting investor meetings throughout the conference.